Guardion Health Sciences, Inc. (GHSI)

$0.158

+0.01 (+7.05%)
Rating:
Recommendation:
-
Symbol GHSI
Price $0.158
Beta 0.794
Volume Avg. 5.28M
Market Cap 9.705M
Shares () -
52 Week Range 0.13-1.98
1y Target Est -
DCF Unlevered GHSI DCF ->
DCF Levered GHSI LDCF ->
ROE -74.80% Strong Sell
ROA -73.26% Strong Sell
Operating Margin -
Debt / Equity 6.02% Neutral
P/E -
P/B 0.35 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GHSI news


Mr. Michael Favish
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.